This is a purely retrospective and observational monocentric study
Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018.
Age ≥ 18 years at enrolment.
Written informed consent (if applicable)
none
Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018
Cohort
Retrospective
Not listed
clinical characteristics of Marginal zone lymphoma patients
to descrive clinical characteristics of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital.
effectiveness
It includes: 1. Description of treatment duration and causes of treatment discontinuation. 2. Description of adverse events / safety of the treatments 3. Assessment of patients' survival. 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions. 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases
safety
It includes: 1. Description of treatment duration and causes of treatment discontinuation. 2. Description of adverse events / safety of the treatments 3. Assessment of patients' survival. 4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions. 5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases
Click on the lead sponsor to view all of their trials.
